Marijuana Stock Soars 130% After Study Shows Its Drug Reduced Seizures
If you aren’t familiar with GW Pharmaceuticals, it is a London-based bio-pharmaceutical company that focuses on researching, developing and then commercializing treatments from its cannabinoid * products derived from the cannabis or marijuana plant. (This contributor owns shares in GWPH).
MAR 14, 2016 @ 01:11 PM
For years GW Pharmaceuticals has looked like one of the only seriously legitimate stocks in the highly hyped so-called pot-stock sector and on Monday the British company gave investors more proof that it was for real.
GW Pharmaceuticals reported that its cannabinoid drug, Epidolex, reduced seizures for children suffering from a rare and debilitating form of epilepsy in a 120-patient trial.
Shares of GW Pharmaceuticals soared on the news, rising 130% to $88.94 on Monday, MAR 14, 2016. …
For years GW Pharmaceuticals has looked like one of the only seriously legitimate stocks in the highly hyped so-called…www.forbes.com